fourth share everyone echo to the Nancy's charting Thank overview and the next the you, present provide clinical about In brief us tumors. AML half steps and Nancy, today. in and how we sentiment, want programs second To data XXXX to promises good a Syros both solid and expect and as joining an morning XXXX. for readouts nature of of of time the additional quarter, to to opportunities in data the to exciting think begin of we advanced data for including in we be I anticipation XXXX the
the XXXX. XX% with higher-risk potential patients approximately has AML broad and MDS for XXXX are who combination RARA-positive. believe We of begin me Let
newly-diagnosed with tolerability is signs independence rapid the transfusion focused XXXX genomically cohort Data newly-diagnosed early on to refractory rates this date longer These or the study. report Phase AML November, expect which in patients. completed action, data with of we combination to of shown we're these frontline subset quarter will II onset high patients and setting. unfit We inform relapsed data on enrollment curing more unfit favorable needed. responses mature treatment are steps Despite frontline the Better from next ongoing in duration trial in in durability. and not patients treatment unfit advances, Our azacitidine in complete still fourth include newly-diagnosed regimens of has defined will of of and patients. and and
an refractory resistance prognosis. to patients the and in are poorer to patients, even some with Some frontline that virtually all therapies mechanisms confer appear cases,
of to which best therapies All data patient to remains patients relapsed cohort less and May, sequence X which need refractory in from or and how the importance active, low respond ongoing with overall well-tolerated therapies for in be as The subsets, of or alternatives. as likely in to than AML therapies. that and those completed to enrollment well refractory Median in patients unmet report identifying can need expect the points therapies combination quarter. used in months first few recently We fourth the cohort at this the patient we stark. to survival is relapsed limited many target this the approved particularly leaving are
patient unmet registrational later that potential the provide setting, need in the decision population, a the this enabling year trial. data into this of relapsed/refractory in moving Given to a about have we the proof-of-concept believe severity the
Turning XXXX. now to
kinase the presented BRAF, very colorectal or colorectal our the of attacks that cancer of XXXX XXXX insights first cycle inhibiting Nancy providing mentioned, played potent preclinical which include well-tolerated mutations for in difficult-to-treat KRAS the are tumor of colorectal increased cancer common in in tumor disease processes, the decided growth both mechanistic in studies. I seen in as patients rationale decision hypothesis cancer out because basis in factors a BRAF-mutant of cell Phase we Map colorectal models The the As our XXXX drivers. We to KRAS-mutant models. both cancer. into of in part oncogenic progression the colorectal inhibited are regressions virtual trial. activating through pathway transcription ongoing explore CDKX, doses activators in with XXXX By cancer for XXXX forms these at and well expression as data role ASCO provided to meeting as and
colorectal been in and to PD we're in work markers supported preclinical efficacy. collective preclinical occupancy Our markers target with also PD ongoing the the with able studies our in correlate cancer have area trial. And using that this
needed Phase I the We markers to understand doses are help that on At the design. patients activity. biologic ASCO, detail are for in measuring trial these additional provided also we
ovarian preclinical you patient patients we alterations. the know, in that trial This approximately with breast, As any lung with initiated histology XXXX harbor models tumors This cohort mechanistic or enroll breast preclinical these open-label based and multicenter cancer, in pathway solid fulvestrant a cancer on with fulvestrant. HR-positive shows colorectal, combination in activity. first dosed the patient to In the on robust focusing combination in RB We're rationale is or with advanced inhibitor our January. trial of XX expected includes CDKX/X populations assess antitumor XXXX to recently resistant the of unmet need. data,
Additionally, our preclinical we've models emerged RB XXXX notably, RB of and with alteration mechanism ovarian altered as sustained of lung to doses study dose and schedule. models. maximum a deeper observed XXXX I in escalating is in alteration with and goal designed a than in studies across And cancer, assess the to breast, tolerated responses the to resistance establishing inhibitors. of and tolerability safety more have non-RB CDKX/X The Phase
safety, and potential predictive and activity, We Additional PD year. in to PK objectives include of initial fourth the antitumor assessments tolerability, quarter PD biomarkers. of record this PK, plan data
mid-XXXX. of dose we initiate activity cohorts cleared We toxicity limited including while escalation XXXX the clinical efficacy the expand design, evaluation escalation is agent. to of trial any and multiple that in report part dose to escalation to level safety Once the And has as flexibility and evaluate expect dose further combination data completed, explore both to expansion the dose at to early data, proceeds. single we signals a cohorts additional have as dose plan
data closer systematically of candidates look two review and our for pass in that our to to patients reflecting bring have our Joe to how call financial goal needed over medicines the second We controlled results chances analyze patients. forward that, deep XXXX I'll in therapeutic on With us to both genes We new programs genes quarter. for the we our and will maximize home market the excellent of to are hope which regions understanding to to of much benefit. reporting bringing to control which for XXXX, ability to a product regulatory providing in
